4
ALL4
Boehringer Ingelheim GmbHYear
4
ALL1
20243
2022DEALS // DEV.
4
ALL4
DevelopmentsCountry
4
ALL4
GERMANY4
ALL4
Not ApplicableTherapeutic Area
4
ALL3
Pulmonary/Respiratory Diseases1
TechnologyStudy Phase
4
ALL1
Approved3
Phase IIIDeal Type
0
ALLProduct Type
4
ALL4
Small moleculeDosage Form
3
ALL1
Film Coated Tablet2
Tablet, Film CoatedLead Product
4
ALL3
BI 10155501
NerandomilastTarget
3
ALL3
PDE4BLead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Boehringer’s Nerandomilast Meets Primary Endpoint in FIBRONEER™-IPF Study
Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.
Brand Name : BI 1015550
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2024
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (ILDs)
Brand Name : BI 1015550
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2022
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Patients with FVC ≥45% predicted, who were either not on antifibrotic therapy or were on a stable dose of antifibrotic therapy for at least 8 weeks before study entry, were randomized 2:1 to receive either BI 1015550 18 mg twice daily or placebo for 12...
Brand Name : BI 1015550
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2022
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Details : This approval is based on results from the landmark EMPEROR-Preserved® phase III trial, which investigated the effect of empagliflozin 10 mg compared with placebo once daily, both on top of standard of care therapy, in 5,988 adults with heart failure wi...
Brand Name : BI 1015550
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2022
Lead Product(s) : Nerandomilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?